您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Buclizine HCl(UCB-4445)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Buclizine HCl(UCB-4445)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Buclizine HCl(UCB-4445)图片
CAS NO:129-74-8
规格:≥98%
包装与价格:
包装价格(元)
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
2g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)505.95
FormulaC28H33ClN2.2HCl
CAS No.129-74-8
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)

Chemical Name: 1-(4-(tert-butyl)benzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine dihydrochloride

InChi Key: SDBHDSZKNVDKNU-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H33ClN2.2ClH/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24;;/h4-16,27H,17-21H2,1-3H3;2*1H

SMILES Code: ClC1=CC=C(C(N2CCN(CC3=CC=C(C(C)(C)C)C=C3)CC2)C4=CC=CC=C4)C=C1.[H]Cl.[H]Cl

SynonymsUCB-4445; AH 2526, UCB4445; AH-2526, UCB 4445; AH2526; Buclizine; Buclizine dihydrochloride; AH-2526, UCB 4445; AH2526;UCB-4445, Buclina, Longifene, Posdel, Vibazine.
实验参考方法
In Vitro

In vitro activity: Buclizine hydrochloride, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. Buclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which buclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.

In Vivo
Animal model
Formulation & Dosage
References

Profiles Drug Subst Excip Relat Methodol. 2011;36:1-33.